Abstract: A method is provided for measuring a permeability of a subject's blood-brain barrier to water. The method includes acquiring, with an magnetic resonance imaging (“MRI”) system, a first T1 map of the subject over at least a selected region-of-interest (“ROI”) including a brain of the subject and waiting a delay period selected to allow an affect of the contrast agent on the longitudinal relaxation period to change. The method then includes acquiring, after expiration of the delay period and with the MRI system, a second T1 map of the subject over at least the selected ROI and determining, using the first T1 map and the second T1 map, a fractional volume of vascular compartments in the ROI and a permeability surface area product in the ROI. The method includes creating, using the determined fractional volume and permeability surface area product, a map of water exchange rate in the ROI.

Abstract: Fibrin-specific imaging agents that contain at least two imaging reporters are described, as well as methods of making and using the contrast agents.

Abstract: The invention relates to novel cascade polymer complexes, to compositions comprising these compounds, to the use of the complexes in NMR diagnosis, and to processes for preparing these compounds and compositions.

Abstract: Diagnostic compositions and methods for imaging collagen and/or assessing myocardial perfusion are described. The diagnostic compositions can include collagen binding peptides.

Abstract: Diagnostic compositions and methods for imaging and/or assessing collagen are described. The diagnostic compositions can include collagen binding peptides.

Abstract: Methods and contrast agents for imaging the lymph system are provided. The methods allow the diagnosis and staging of diseases of the lymph system, such as cancer and infections.

Abstract: Peptides capable of binding to extracellular matrix proteins, such as collagen, are described, including their use in diagnostic and therapeutic applications.

Abstract: Organic chelating ligands, organic chelating ligand precursors, and metal chelates are disclosed. Methods for synthesizing the same are also described, including methods for preparing optically-enriched or optically-pure compositions of the same.

Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

Abstract: Chelating ligands and metal chelates useful as CEST MR contrast agents are disclosed. The CEST agents can be used to evaluate blood volume changes in the heart and brain.

Abstract: Organic chelating ligands, organic chelating ligand precursors, and metal chelates are disclosed. Methods for synthesizing the same are also described, including methods for preparing optically-enriched or optically-pure compositions of the same.

Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

Abstract: Peptides and peptide-targeted multimeric contrast agents are described, as well as methods of making and using the contrast agents.

Abstract: The present invention relates to contrast agents for diagnostic imaging. In particular, this invention relates to novel multimeric compounds which exhibit improved relaxivity properties upon binding to endogenous proteins or other physiologically relevant sites. The compounds consist of: a) two or more Image Enhancing Moieties (IEMs) (or signal-generating moiety) comprising multiple subunits; b) two or more Target Binding Moieties (TBMs), providing for in vivo localization and multimer rigidification; and c) a scaffold framework for attachment of the above moieties. d) optional linkers for attachment of the IEMs to scaffold. This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for contrast enhancement of diagnostic imaging.